Literature DB >> 9754697

Plasma neuropeptide-Y levels, monoamine metabolism, electrolyte excretion and drinking behavior in children with attention-deficit hyperactivity disorder.

R D Oades1, R Daniels, W Rascher.   

Abstract

Against a background of (a) increased drinking behavior in children with attention-deficit hyperactivity disorder (ADHD); (b) the parallel between some behaviors associated with ADHD and hypertension; (c) the use of the spontaneously hypertensive rat as a model for ADHD; and (d) similarities in the changes of neuropeptide Y (NPY) and catecholamine in studies of hypertension and drinking, NPY, catecholamines and electrolyte balance were compared in the plasma and urine of healthy children and those with ADHD. Drinking was monitored during 3 h of neuropsychological tests over 2 days in 14 ADHD and nine healthy children. Patients drank four times as much water and showed twice the levels of NPY found in controls. In controls there were positive and in patients there were negative relationships for NPY with drinking and restless behavior. Patients' plasma levels of norepinephrine (NE) and epinephrine were slightly elevated, but urinary levels of NE and the serotonin metabolite were markedly increased. Urinary excretion rates for sodium (not potassium), phosphate and especially calcium were decreased in patients even after covarying for less urine production in the ADHD group. NPY levels were inversely related to calcium excretion and drinking was inversely related to circulating sodium. Increases of drinking and circulating NPY in ADHD children and decreased electrolyte excretion may reflect a common disturbance in metabolic homeostasis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9754697     DOI: 10.1016/s0165-1781(98)00064-x

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  11 in total

1.  Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder.

Authors:  Josephine Elia; Joseph T Glessner; Kai Wang; Nagahide Takahashi; Corina J Shtir; Dexter Hadley; Patrick M A Sleiman; Haitao Zhang; Cecilia E Kim; Reid Robison; Gholson J Lyon; James H Flory; Jonathan P Bradfield; Marcin Imielinski; Cuiping Hou; Edward C Frackelton; Rosetta M Chiavacci; Takeshi Sakurai; Cara Rabin; Frank A Middleton; Kelly A Thomas; Maria Garris; Frank Mentch; Christine M Freitag; Hans-Christoph Steinhausen; Alexandre A Todorov; Andreas Reif; Aribert Rothenberger; Barbara Franke; Eric O Mick; Herbert Roeyers; Jan Buitelaar; Klaus-Peter Lesch; Tobias Banaschewski; Richard P Ebstein; Fernando Mulas; Robert D Oades; Joseph Sergeant; Edmund Sonuga-Barke; Tobias J Renner; Marcel Romanos; Jasmin Romanos; Andreas Warnke; Susanne Walitza; Jobst Meyer; Haukur Pálmason; Christiane Seitz; Sandra K Loo; Susan L Smalley; Joseph Biederman; Lindsey Kent; Philip Asherson; Richard J L Anney; J William Gaynor; Philip Shaw; Marcella Devoto; Peter S White; Struan F A Grant; Joseph D Buxbaum; Judith L Rapoport; Nigel M Williams; Stanley F Nelson; Stephen V Faraone; Hakon Hakonarson
Journal:  Nat Genet       Date:  2011-12-04       Impact factor: 38.330

2.  Activation of serotonin 5-HT2A receptors inhibits high compulsive drinking on schedule-induced polydipsia.

Authors:  Silvia Victoria Navarro; Valeria Gutiérrez-Ferre; Pilar Flores; Margarita Moreno
Journal:  Psychopharmacology (Berl)       Date:  2014-08-26       Impact factor: 4.530

Review 3.  Schedule-induced polydipsia as a model of compulsive behavior: neuropharmacological and neuroendocrine bases.

Authors:  Margarita Moreno; Pilar Flores
Journal:  Psychopharmacology (Berl)       Date:  2011-11-24       Impact factor: 4.530

4.  Poor inhibitory control and neurochemical differences in high compulsive drinker rats selected by schedule-induced polydipsia.

Authors:  Margarita Moreno; Valeria Edith Gutiérrez-Ferre; Luis Ruedas; Leticia Campa; Cristina Suñol; Pilar Flores
Journal:  Psychopharmacology (Berl)       Date:  2011-11-24       Impact factor: 4.530

Review 5.  Biomarkers in the diagnosis of ADHD--promising directions.

Authors:  Stephen V Faraone; Cristian Bonvicini; Catia Scassellati
Journal:  Curr Psychiatry Rep       Date:  2014-11       Impact factor: 5.285

Review 6.  Unraveling the mechanisms responsible for the comorbidity between metabolic syndrome and mental health disorders.

Authors:  Elizabeth K Nousen; Juliana G Franco; Elinor L Sullivan
Journal:  Neuroendocrinology       Date:  2013-09-21       Impact factor: 4.914

7.  Steroid sulfatase-deficient mice exhibit endophenotypes relevant to attention deficit hyperactivity disorder.

Authors:  Simon Trent; Alison Dennehy; Heather Richardson; Obah A Ojarikre; Paul S Burgoyne; Trevor Humby; William Davies
Journal:  Psychoneuroendocrinology       Date:  2011-07-01       Impact factor: 4.905

8.  Response variability in Attention-Deficit/Hyperactivity Disorder: a neuronal and glial energetics hypothesis.

Authors:  Vivienne A Russell; Robert D Oades; Rosemary Tannock; Peter R Killeen; Judith G Auerbach; Espen B Johansen; Terje Sagvolden
Journal:  Behav Brain Funct       Date:  2006-08-23       Impact factor: 3.759

9.  The influence of serotonin- and other genes on impulsive behavioral aggression and cognitive impulsivity in children with attention-deficit/hyperactivity disorder (ADHD): Findings from a family-based association test (FBAT) analysis.

Authors:  Robert D Oades; Jessica Lasky-Su; Hanna Christiansen; Stephen V Faraone; Edmund Js Sonuga-Barke; Tobias Banaschewski; Wai Chen; Richard Jl Anney; Jan K Buitelaar; Richard P Ebstein; Barbara Franke; Michael Gill; Ana Miranda; Herbert Roeyers; Aribert Rothenberger; Joseph A Sergeant; Hans-Christoph Steinhausen; Eric A Taylor; Margaret Thompson; Philip Asherson
Journal:  Behav Brain Funct       Date:  2008-10-20       Impact factor: 3.759

10.  Enhanced inhibitory control by neuropeptide Y Y5 receptor blockade in rats.

Authors:  A Bari; A Dec; A W Lee; J Lee; D Song; E Dale; J Peterson; S Zorn; X Huang; B Campbell; T W Robbins; A R West
Journal:  Psychopharmacology (Berl)       Date:  2014-09-07       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.